Nivolumab in Lung Cancer Shows Unprecedented Survival Nivolumab in Lung Cancer Shows Unprecedented Survival
Another phase 3 study has shown a survival benefit for the immunotherapy nivolumab compared with chemotherapy with docetaxel. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hematology | Lung Cancer | Study | Taxotere